Skip to main content

Advertisement

SpringerLink
Log in

Antihypertensive agents for aging patients who are at risk for cognitive dysfunction

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Observational and experimental data continue to accumulate about the impact of blood pressure (BP) and antihypertensive agents on cognitive function. Current evidence suggests that there is a U-shaped association between BP earlier in life and poor cognitive function and clinical dementia, including Alzheimer’s disease. This association has been identified more consistently in longitudinal surveys due to the fact that BP declines when cognitive symptoms start. Lowering BP provides protection against this complication of high BP. This effect is present in the cognitively intact and in those with dementia. Antihypertensives that cross the blood brain barrier and affect the renin-angiotensin-aldosterone system (such as perindopril or losartan) or brain calcium metabolism (nitrendipine) provide additional protection beyond BP control against cognitive decline. These drugs may be preferred in such clinical situations

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kilander L, Nyman H, Boberg M, et al.: Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998, 31:780–786.

    PubMed  CAS  Google Scholar 

  2. Petitti DB, Crooks VC, Buckwalter JG, Chiu V: Blood pressure levels before dementia. Arch Neurol 2005, 62:112–116.

    Article  PubMed  Google Scholar 

  3. Paran E, Anson O, Reuveni H: Blood pressure and cognitive functioning among independent elderly. Am J Hypertens 2003, 16:818–826.

    Article  PubMed  Google Scholar 

  4. Elias MF, Wolf PA, D’Agostino RB, et al.: Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993, 138:353–364.

    PubMed  CAS  Google Scholar 

  5. Launer LJ, Masaki K, Petrovitch H, et al.: The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995, 274:1846–1851.

    Article  PubMed  CAS  Google Scholar 

  6. Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A: Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology 1999, 53:1948–1952.

    PubMed  CAS  Google Scholar 

  7. Knopman D, Boland LL, Mosley T, et al.: Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001, 56:42–48.

    PubMed  CAS  Google Scholar 

  8. Saxby BK, Harrington F, McKeith IG, et al.: Effects of hypertension on attention, memory, and executive function in older adults. Health Psychol 2003, 22:587–591.

    Article  PubMed  Google Scholar 

  9. Desmond DW, Tatemichi TK, Paik M, Stern Y: Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. Arch Neurol 1993, 50:162–166.

    PubMed  CAS  Google Scholar 

  10. Waldstein SR, Manuck SB, Ryan CM, Muldoon MF: Neuropsychological correlates of hypertension: review and methodologic considerations. Psychol Bull 1991, 110:451–468.

    Article  PubMed  CAS  Google Scholar 

  11. Kuo HK, Sorond F, Iloputaife I, et al.: Effect of blood pressure on cognitive functions in elderly persons. J Gerontol A Biol Sci Med Sci 2004, 59:1191–1194.

    PubMed  Google Scholar 

  12. Scherr PA, Hebert LE, Smith LA, Evans DA: Relation of blood pressure to cognitive function in the elderly. Am J Epidemiol 1991, 134:1303–1315.

    PubMed  CAS  Google Scholar 

  13. Pandav R, Dodge HH, DeKosky ST, Ganguli M: Blood pressure and cognitive impairment in India and the United States: a cross-national epidemiological study. Arch Neurol 2003, 60:1123–1128.

    Article  PubMed  Google Scholar 

  14. Skoog I, Lernfelt B, Landahl S, et al.: 15-year longitudinal study of blood pressure and dementia. Lancet 1996, 347:1141–1145.

    Article  PubMed  CAS  Google Scholar 

  15. Reinprecht F, Elmstahl S, Janzon L, Andre-Petersson L: Hypertension and changes of cognitive function in 81-year-old men: a 13-year follow-up of the population study “Men born in 1914,” Sweden. J Hypertens 2003, 21:57–66.

    Article  PubMed  CAS  Google Scholar 

  16. Glynn RJ, Beckett LA, Hebert LE, et al.: Current and remote blood pressure and cognitive decline. JAMA 1999, 281:438–445.

    Article  PubMed  CAS  Google Scholar 

  17. Hebert LE, Scherr PA, Bennett DA, et al.: Blood pressure and late-life cognitive function change: a biracial longitudinal population study. Neurology 2004, 62:2021–2024.

    PubMed  CAS  Google Scholar 

  18. Elias MF, Elias PK, Sullivan LM, et al.: Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord 2003, 27:260–268.

    Article  PubMed  CAS  Google Scholar 

  19. Yaffe K, Kanaya A, Lindquist K, et al.: The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292:2237–2242.

    Article  PubMed  CAS  Google Scholar 

  20. Kang JH, Logroscino G, De Vivo I, et al.: Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiol Aging 2005, 26:475–484.

    Article  PubMed  CAS  Google Scholar 

  21. Waldstein SR, Katzel LI: Gender differences in the relation of hypertension to cognitive function in older adults. Neurol Res 2004, 26:502–506.

    Article  PubMed  Google Scholar 

  22. Kivipelto M, Helkala EL, Laakso MP, et al.: Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001, 322:1447–1451.

    Article  PubMed  CAS  Google Scholar 

  23. Whitmer RA, Sidney S, Selby J, et al.: Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005, 64:277–281.

    PubMed  CAS  Google Scholar 

  24. Schmidt R, Fazekas F, Koch M, et al.: Magnetic resonance imaging cerebral abnormalities and neuropsychologic test performance in elderly hypertensive subjects: a case-control study. Arch Neurol 1995, 52:905–910.

    PubMed  CAS  Google Scholar 

  25. Fernando MS, Ince PG: Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci 2004, 226:13–17.

    Article  PubMed  Google Scholar 

  26. van Dijk EJ, Breteler MM, Schmidt R, et al.: The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004, 44:625–630.

    Article  PubMed  CAS  Google Scholar 

  27. Korf ES, White LR, Scheltens P, Launer LJ: Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension 2004, 44:29–34.

    Article  PubMed  CAS  Google Scholar 

  28. Bellew KM, Pigeon JG, Stang PE, et al.: Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 2004, 18:208–213.

    PubMed  Google Scholar 

  29. Skoog I, Andreasson LA, Landahl S, Lernfelt B: A populationbased study on blood pressure and brain atrophy in 85-yearolds. Hypertension 1998, 32:404–409.

    PubMed  CAS  Google Scholar 

  30. Guo Z, Viitanen M, Fratiglioni L, Winblad B: Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ 1996, 312:805–808.

    PubMed  CAS  Google Scholar 

  31. Larson EB, Kukull WA, Buchner D, Reifler BV: Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med 1987, 107:169–173.

    PubMed  CAS  Google Scholar 

  32. Barnes JM, Barnes NM, Costall B, et al.: Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res 1989, 491:136–143.

    Article  PubMed  CAS  Google Scholar 

  33. Gerhardt P, Hasenohrl RU, Hock FJ, Huston JP: Mnemogenic effects of injecting RA-octil, a CE-inhibitor derivate, systemically or into the basal forebrain. Psychopharmacology (Berl) 1993, 111:442–448.

    Article  CAS  Google Scholar 

  34. Braszko JJ, Paslawski L, Karwowska-Polecka W, Holownia A: Trandolapril attenuates acquisition of conditioned avoidance in rats. Pol J Pharmacol 2000, 52:195–201.

    PubMed  CAS  Google Scholar 

  35. Hirawa N, Uehara Y, Kawabata Y, et al.: Long-term inhibition of renin-angiotensin system sustains memory function in aged Dahl rats. Hypertension 1999, 34:496–502.

    PubMed  CAS  Google Scholar 

  36. Raghavendra V, Chopra K, Kulkarni SK: Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory. Neuropeptides 1998, 32:417–421.

    Article  PubMed  CAS  Google Scholar 

  37. Murray MD, Lane KA, Gao S, et al.: Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 2002, 162:2090–2096. This is a key study that investigated the impact of antihypertensives on cognitive function. It includes US black participants, whom have not been commonly included in previous studies.

    Article  PubMed  Google Scholar 

  38. Hajjar I, Catoe H, Sixta S, et al.: Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol A Biol Sci Med Sci 2005, 60:67–73.

    PubMed  Google Scholar 

  39. in’t Veld BA, Ruitenberg A, Hofman A, et al.: Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001, 22:407–412.

    Article  Google Scholar 

  40. Waldstein SR, Giggey PP, Thayer JF, Zonderman AB: Nonlinear relations of blood pressure to cognitive function: the Baltimore Longitudinal Study of Aging. Hypertension 2005, 45:374–379.

    Article  PubMed  CAS  Google Scholar 

  41. Myron F, Weiner FJB, Ron Tintner, et al.: ACE inhibitor lacks acute effect on cognition or brain blood flow in Alzheimer’s disease. Drug Dev Res 1992, 26:467–471.

    Article  Google Scholar 

  42. Louis WJ, Mander AG, Dawson M, et al.: Use of computerized neuropsychological tests (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly. Cambridge Neuropsychological Test Automated Battery. J Hypertens 1999, 17(12 Pt 2):1813–1819.

    Article  PubMed  CAS  Google Scholar 

  43. Muldoon MF, Waldstein SR, Ryan CM, et al.: Effects of six antihypertensive medications on cognitive performance. J Hypertens 2002, 20:1643–1652.

    Article  PubMed  CAS  Google Scholar 

  44. Ohrui T, Matsui T, Yamaya M, et al.: Angiotensin-converting enzyme inhibitors and incidence of Alzheimer’s disease in Japan. J Am Geriatr Soc 2004, 52:649–650.

    Article  PubMed  Google Scholar 

  45. Applegate WB, Pressel S, Wittes J, et al.: Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the Systolic Hypertension in the Elderly Program. Arch Intern Med 1994, 154:2154–2160.

    Article  PubMed  CAS  Google Scholar 

  46. Prince MJ, Bird AS, Blizard RA, Mann AH: Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s trial of hypertension in older adults. BMJ 1996, 312:801–805.

    PubMed  CAS  Google Scholar 

  47. Forette F, Seux ML, Staessen JA, et al.: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347–51.

    Article  PubMed  CAS  Google Scholar 

  48. Forette F, Seux ML, Staessen JA, et al.: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002, 162:2046–2052. This trial, an extension of Forette et al. [47], is key because it shows the persistent delayed effect on dementia and AD in hypertension management with nitrendipine.

    Article  PubMed  Google Scholar 

  49. Fogari R, Mugellini A, Zoppi A, et al.: Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004, 59:863–868.

    Article  PubMed  CAS  Google Scholar 

  50. Tzourio C, Anderson C, Chapman N, et al.: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163:1069–1075.

    Article  PubMed  CAS  Google Scholar 

  51. Bosch J, Yusuf S, Pogue J, et al.: Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002, 324:699–702.

    Article  PubMed  CAS  Google Scholar 

  52. Lithell H, Hansson L, Skoog I, et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875–886.

    Article  PubMed  CAS  Google Scholar 

  53. Fogari R, Mugellini A, Zoppi A, et al.: Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 2003, 17:781–785.

    Article  PubMed  CAS  Google Scholar 

  54. Tedesco MA, Ratti G, Mennella S, et al.: Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999, 12:1130–1134.

    Article  PubMed  CAS  Google Scholar 

  55. Feigin V, Ratnasabapathy Y, Anderson C: Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci 2005, 229-230:151–155.

    Article  PubMed  Google Scholar 

  56. Lipsitz LA, Gagnon M, Vyas M, et al.: Antihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects. Hypertension 2005, 45:216–221.

    Article  PubMed  CAS  Google Scholar 

  57. Khachaturian ZS: Calcium hypothesis of Alzheimer’s disease and brain aging. Ann N Y Acad Sci 1994, 747:1–11.

    Article  PubMed  CAS  Google Scholar 

  58. O’Neill C, Cowburn RF, Bonkale WL, et al.: Dysfunctional intracellular calcium homoeostasis: a central cause of neurodegeneration in Alzheimer’s disease. Biochem Soc Symp 2001:177–194.

  59. Mattson MP, Cheng B, Davis D, et al.: beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992, 12:376–389.

    PubMed  CAS  Google Scholar 

  60. Iwai M, Liu HW, Chen R, et al.: Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004, 110:843–848.

    Article  PubMed  CAS  Google Scholar 

  61. Hatazawa J, Shimosegawa E, Osaki Y, et al.: Long-term angiotensin-converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke. Stroke 2004, 35:2117–2122. This is a key study because it shows the effect of ACE inhibition on CBF, a key factor in BP control and cognitive function.

    Article  PubMed  CAS  Google Scholar 

  62. Kazama K, Anrather J, Zhou P, et al.: Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 2004, 95:1019–1026.

    Article  PubMed  CAS  Google Scholar 

  63. Savaskan E, Hock C, Olivieri G, et al.: Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia. Neurobiol Aging 2001, 22:541–546.

    Article  PubMed  CAS  Google Scholar 

  64. Amouyel P, Richard F, Cottel D, et al.: The deletion allele of the angiotensin I converting enzyme gene as a genetic susceptibility factor for cognitive impairment. Neurosci Lett 1996, 217:203–205.

    Article  PubMed  CAS  Google Scholar 

  65. Thomas T, Thomas G, McLendon C, et al.: beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996, 380:168–171.

    Article  PubMed  CAS  Google Scholar 

  66. Bookheimer SY, Strojwas MH, Cohen MS, et al.: Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med 2000, 343:450–456.

    Article  PubMed  CAS  Google Scholar 

  67. Kogure D, Matsuda H, Ohnishi T, et al.: Longitudinal evaluation of early Alzheimer’s disease using brain perfusion SPECT. J Nucl Med 2000, 41:1155–1162.

    PubMed  CAS  Google Scholar 

  68. Johnson KA, Jones K, Holman BL, et al.: Preclinical prediction of Alzheimer’s disease using SPECT. Neurology 1998, 50:1563–1571.

    PubMed  CAS  Google Scholar 

  69. Bailey TL, Rivara CB, Rocher AB, Hof PR: The nature and effects of cortical microvascular pathology in aging and Alzheimer’s disease. Neurol Res 2004, 26:573–578.

    Article  PubMed  Google Scholar 

  70. Vinters HV, Farag ES: Amyloidosis of cerebral arteries. Adv Neurol 2003, 92:105–112.

    PubMed  Google Scholar 

  71. Farkas E, Luiten PG: Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog Neurobiol 2001, 64:575–611.

    Article  PubMed  CAS  Google Scholar 

  72. Deane R, Du Yan S, Submamaryan RK, et al.: RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003, 9:907–913.

    Article  PubMed  CAS  Google Scholar 

  73. Zlokovic BV: Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci 2005, 28:202–208.

    Article  PubMed  CAS  Google Scholar 

  74. Kemper TL, Blatt GJ, Killiany RJ, Moss MB: Neuropathology of progressive cognitive decline in chronically hypertensive rhesus monkeys. Acta Neuropathol (Berlin) 2001, 101:145–153.

    CAS  Google Scholar 

  75. Farmer ME, Kittner SJ, Abbott RD, et al.: Longitudinally measured blood pressure, antihypertensive medication use, and cognitive performance: the Framingham Study. J Clin Epidemiol 1990, 43:475–480.

    Article  PubMed  CAS  Google Scholar 

  76. Guo Z, Fratiglioni L, Zhu L, et al.: Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 1999, 56:991–996.

    Article  PubMed  CAS  Google Scholar 

  77. Muldoon MF, Manuck SB, Shapiro AP, Waldstein SR: Neurobehavioral effects of antihypertensive medications. J Hypertens 1991, 9:549–559.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Palmetto Health Richland/University of South Carolina, 9 Medical Park Drive, Suite 230, 29203, Columbia, SC, USA

    Ihab Hajjar MD, MS, Michelle Keown BS & Brandy Frost FNP, ND

Authors
  1. Ihab Hajjar MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle Keown BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brandy Frost FNP, ND
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hajjar, I., Keown, M. & Frost, B. Antihypertensive agents for aging patients who are at risk for cognitive dysfunction. Current Science Inc 7, 466–473 (2005). https://doi.org/10.1007/s11906-005-0043-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-005-0043-y

Keywords

Search

Navigation